Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M
Department of Obstetrics and Gynecology, Jichi Medical School, School of Medicine, Tochigi, Japan.
Obstet Gynecol. 1993 Dec;82(6):946-50.
To determine the serum level of macrophage colony-stimulating factor in ovarian cancer patients in order to evaluate its role as a marker for ovarian cancer.
Serum macrophage colony-stimulating factor levels were assayed in 69 patients with epithelial ovarian cancer, 55 with benign ovarian tumors, and 634 healthy individuals, including 398 women, using an enzyme-linked immunosorbent assay.
The average serum macrophage colony-stimulating factor level was 754.4 +/- 153.9 U/mL in healthy females; 1056 U/mL (mean plus 1.96 standard deviations) was considered to be the upper limit of normal. Serum macrophage colony-stimulating factor levels were significantly elevated in patients with ovarian cancer (average 1460.5 +/- 1006.2 U/mL; P < .001) and exceeded 1056 U/mL in 42 of the 69 patients with ovarian cancer (61%). No differences in levels were observed among the histologic types. No definite relationship was found between serum levels of macrophage colony-stimulating factor and those of CA 125. We found that 96% of the patients with ovarian cancer had high serum levels of macrophage colony-stimulating factor and/or CA 125 values. There was no significant difference in the levels of macrophage colony-stimulating factor between patients with benign ovarian tumors and healthy controls. Only 7.3% of the group with benign tumors had levels exceeding 1056 U/mL.
Macrophage colony-stimulating factor is a marker for ovarian cancer. Determination of serum levels can be useful in detecting ovarian cancer, particularly in combination with CA 125.
测定卵巢癌患者血清中巨噬细胞集落刺激因子水平，以评估其作为卵巢癌标志物的作用。
采用酶联免疫吸附测定法，对69例上皮性卵巢癌患者、55例良性卵巢肿瘤患者及634名健康个体（包括398名女性）的血清巨噬细胞集落刺激因子水平进行检测。
健康女性血清巨噬细胞集落刺激因子平均水平为754.4±153.9 U/mL；1056 U/mL（均值加1.96个标准差）被视为正常上限。卵巢癌患者血清巨噬细胞集落刺激因子水平显著升高（平均1460.5±1006.2 U/mL；P<.001），69例卵巢癌患者中有42例（61%）超过1056 U/mL。各组织学类型之间水平无差异。未发现血清巨噬细胞集落刺激因子水平与CA 125水平之间存在明确关系。我们发现96%的卵巢癌患者血清巨噬细胞集落刺激因子水平和/或CA 125值较高。良性卵巢肿瘤患者与健康对照者的巨噬细胞集落刺激因子水平无显著差异。良性肿瘤组中只有7.3%的患者水平超过1056 U/mL。
巨噬细胞集落刺激因子是卵巢癌的标志物。测定血清水平有助于检测卵巢癌，尤其是与CA 125联合检测时。
